EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Initial ribociclib plus endocrine therapy for HR +/ HER2 − advanced breast cancer in pre‐ and postmenopausal Chinese women: Primary results from a phase 2 randomized study

Zhimin Shao iD, Zhongsheng Tong, Qiang Liu, Wei Li iD, Li Cai, Kunwei Shen, Huiping Li iD, Chuan Wang, Jin Yang, Zhenchuan Song, Shui Wang iD, Ting Luo und 10 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.7408 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Zhimin Shao und 21 weiteren Autor:innen. Beteiligte Einrichtung: Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Aminopyridines, Breast Neoplasms, Purines, Postmenopause. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The MONALEESA‐7 and ‐2 phase 3 randomized trials demonstrated a statistically significant progression‐free survival (PFS) and overall survival (OS) benefit with initial ribociclib + endocrine therapy (ET) versus placebo + ET in pre‐ and postmenopausal patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC), respectively. Similar trends were observed in Asian subgroup analyses. This phase 2 bridging study of initial ET + ribociclib enrolled pre‐ and postmenopausal patients with HR+/HER2– ABC from China and was conducted to demonstrate consistency of PFS results in a Chinese population relative to the global MONALEESA‐7 and ‐2 studies.

Methods

Patients were randomized (1:1) to ET (nonsteroidal aromatase inhibitor + goserelin for premenopausal patients; letrozole for postmenopausal patients) + either ribociclib or placebo. The primary endpoint was investigator‐assessed PFS.

Results

As of April 25, 2022, the median follow‐up was 34.7 months in both cohorts. In the premenopausal cohort, median PFS was 27.6 months in the ribociclib arm ( n = 79) versus 14.7 months in the placebo arm ( n = 77) (hazard ratio 0.67 [95% CI: 0.45, 1.01]). In the postmenopausal cohort, median PFS was not reached in the ribociclib arm versus 18.5 months in the placebo arm ( n = 77 in each arm) (hazard ratio 0.40 [95% CI: 0.26, 0.62]). Data also suggested improvements in secondary efficacy endpoints, although OS data were not mature. The safety profile in this population was consistent with that in global studies.

Conclusions

These data demonstrate a favorable benefit–risk profile for ribociclib + ET in Chinese patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminopyridinesBreast NeoplasmsPurinesPostmenopauseErb-b2 Receptor Tyrosine KinasesAntineoplastic Combined Chemotherapy ProtocolsReceptors, EstrogenLetrozoleHumansFemaleMiddle AgedAdultChinaAgedReceptors, ProgesteronePremenopauseProgression-Free SurvivalGoserelinAromatase InhibitorsEast Asian People

Substanzen

AminopyridinesPurinesErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenLetrozoleReceptors, ProgesteroneGoserelinAromatase InhibitorsribociclibERBB2 protein, human

Autor:innen und Institutionen

  • Fudan University Shanghai Cancer Center, Shanghai, China.
  • Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
  • The First Bethune Hospital of Jilin University, Changchun, China.
  • Harbin Medical University Cancer Hospital, Harbin, China.
  • RuiJin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Zhimin Shao, Wei Li, Huiping Li, Shui Wang, Xiaohua Zeng

Förderung

  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Shao, Z., Tong, Z., Liu, Q., Li, W., Cai, L., Shen, K., Li, H., Wang, C., Yang, J., Song, Z., Wang, S., Luo, T., Zhao, W., Wang, H., Pan, Y., Nie, J., Zeng, X., Bai, Y., Chiang, W., …, & Xu, B. (2024). Initial ribociclib plus endocrine therapy for HR +/ HER2 − advanced breast cancer in pre‐ and postmenopausal Chinese women: Primary results from a phase 2 randomized study. Cancer Medicine. https://doi.org/10.1002/cam4.7408

Vancouver

Shao Z, Tong Z, Liu Q, Li W, Cai L, Shen K, et al. Initial ribociclib plus endocrine therapy for HR +/ HER2 − advanced breast cancer in pre‐ and postmenopausal Chinese women: Primary results from a phase 2 randomized study. Cancer Medicine. 2024. doi:10.1002/cam4.7408

BibTeX
@article{Shao2024,
  author = {Shao, Zhimin and Tong, Zhongsheng and Liu, Qiang and Li, Wei and Cai, Li and Shen, Kunwei and Li, Huiping and Wang, Chuan and Yang, Jin and Song, Zhenchuan and Wang, Shui and Luo, Ting and Zhao, Wenhe and Wang, Haibo and Pan, Yueyin and Nie, Jianyun and Zeng, Xiaohua and Bai, Yanqing and Chiang, Wendy and Guarnaccia, Valeria and Bi, Yu and Xu, Binghe},
  title = {Initial ribociclib plus endocrine therapy for HR +/ HER2 − advanced breast cancer in pre‐ and postmenopausal Chinese women: Primary results from a phase 2 randomized study},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7408}
}
Kostenlos starten →